BidaskClub downgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a report released on Saturday, January 6th.
A number of other analysts have also commented on the company. Chardan Capital reaffirmed a buy rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Zacks Investment Research raised Assembly Biosciences from a hold rating to a buy rating and set a $37.00 price objective for the company in a report on Wednesday, November 15th. Jefferies Group initiated coverage on Assembly Biosciences in a report on Wednesday, November 8th. They set a buy rating and a $50.00 price objective for the company. B. Riley initiated coverage on Assembly Biosciences in a report on Friday, January 5th. They set a neutral rating and a $35.00 price objective for the company. Finally, ValuEngine lowered Assembly Biosciences from a hold rating to a sell rating in a report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $39.25.
Shares of Assembly Biosciences (ASMB) traded up $0.54 during trading hours on Friday, hitting $45.20. The stock had a trading volume of 73,703 shares, compared to its average volume of 107,213. The firm has a market cap of $899.04, a P/E ratio of -15.22 and a beta of 0.91. Assembly Biosciences has a 12 month low of $13.69 and a 12 month high of $52.37.
In other news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $49.37, for a total value of $49,370.00. Following the completion of the transaction, the director now directly owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 4,000 shares of company stock valued at $157,660. 19.60% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio grew its holdings in shares of Assembly Biosciences by 66.9% in the third quarter. Strs Ohio now owns 22,700 shares of the biopharmaceutical company’s stock valued at $792,000 after acquiring an additional 9,100 shares in the last quarter. AXA bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $2,477,000. JPMorgan Chase & Co. bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $3,426,000. California Public Employees Retirement System grew its holdings in shares of Assembly Biosciences by 118.3% in the second quarter. California Public Employees Retirement System now owns 24,540 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 13,300 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Assembly Biosciences by 21.2% in the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after acquiring an additional 107,065 shares in the last quarter. 61.41% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thelincolnianonline.com/2018/01/13/assembly-biosciences-asmb-lowered-to-hold-at-bidaskclub-updated.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.